GMAB Genmab A/S

NASDAQ
$50.97

Genmab A/S (GMAB) is expected to report earnings on February 4, 2027, during market hours. The consensus earnings estimate is $0.23 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -7.5% since its last earnings release on November 5, 2026.

Genmab A/S Beat Consensus Estimates
Thursday, November 5, 2026 · 11:01 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 4
Thursday · Market Hours
Earnings Whisper
-
vs $0.23
Rev est $1.24B
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $53.12

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Genmab A/S

Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage. Genmab A/S is based in Copenhagen V, Denmark.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.